Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer
This is the largest real-world study assessing the efficacy of subsequent chemotherapy in patients progressing during PARPi exposure. The patients have poor outcomes. PBC is the best option in patients progressing on PARPi and eligible for PBC rechallenge (PFI >6 months).
Authors
- Catherine Guérin‐Charbonnel (ORCID: https://orcid.org/0000-0001-7493-4314)
- P. Augereau
- Geoff Hall (ORCID: https://orcid.org/0000-0002-8864-5932)
- Morgan Zenatri
- Alexandra Léary (ORCID: https://orcid.org/0000-0002-2043-2244)
- François C. Bocquet (ORCID: https://orcid.org/0000-0002-9471-4439)
- B. Hanvic
- Paul Milan Kubelac (ORCID: https://orcid.org/0000-0001-7957-9796)
- I. Ray-Coquard
- Jean‐Sébastien Frenel (ORCID: https://orcid.org/0000-0002-5273-0561)
- Patriciu Achimaș-Cădariu (ORCID: https://orcid.org/0000-0001-9928-5883)
- Hayley Fenton (ORCID: https://orcid.org/0000-0001-7824-2614)
- Alexandre Xu-Vuillard
- Ana-Maria-Lacrima Sturz-Lazar
- Sue Cheeseman (ORCID: https://orcid.org/0000-0002-9671-4715)
Institutions
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Leeds Teaching Hospitals NHS Trust (GB)
- Institut Gustave Roussy (FR)
- IQVIA (United Kingdom) (GB)
- Sorbonne Université (FR)
- Institute of Oncology Prof. Dr. Ion Chiricuta (RO)
- Centre Léon Bérard (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Laboratoire Médiations (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103694
- Citations
- 8
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Pfizer
- GlaxoSmithKline
- Gilead Sciences
- Clovis Oncology
- Fox Chase Cancer Center